JP4999330B2 - サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法 - Google Patents
サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法 Download PDFInfo
- Publication number
- JP4999330B2 JP4999330B2 JP2005517263A JP2005517263A JP4999330B2 JP 4999330 B2 JP4999330 B2 JP 4999330B2 JP 2005517263 A JP2005517263 A JP 2005517263A JP 2005517263 A JP2005517263 A JP 2005517263A JP 4999330 B2 JP4999330 B2 JP 4999330B2
- Authority
- JP
- Japan
- Prior art keywords
- virus
- rna
- cells
- dna
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000701022 Cytomegalovirus Species 0.000 title claims description 38
- 238000004519 manufacturing process Methods 0.000 title claims description 38
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 title claims description 27
- 239000003623 enhancer Substances 0.000 title claims description 19
- 239000013603 viral vector Substances 0.000 title description 48
- 210000004027 cell Anatomy 0.000 claims description 265
- 108090000623 proteins and genes Proteins 0.000 claims description 240
- 241000700605 Viruses Species 0.000 claims description 156
- 238000000034 method Methods 0.000 claims description 120
- 241000711408 Murine respirovirus Species 0.000 claims description 97
- 102000004169 proteins and genes Human genes 0.000 claims description 95
- 239000013598 vector Substances 0.000 claims description 90
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 51
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 50
- 230000014509 gene expression Effects 0.000 claims description 49
- 230000000295 complement effect Effects 0.000 claims description 43
- 230000003612 virological effect Effects 0.000 claims description 43
- 230000035897 transcription Effects 0.000 claims description 36
- 238000013518 transcription Methods 0.000 claims description 36
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 35
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 35
- 108010091086 Recombinases Proteins 0.000 claims description 30
- 102000018120 Recombinases Human genes 0.000 claims description 30
- 210000004962 mammalian cell Anatomy 0.000 claims description 21
- 241001515965 unidentified phage Species 0.000 claims description 21
- 239000000470 constituent Substances 0.000 claims description 20
- 230000002950 deficient Effects 0.000 claims description 11
- 210000000349 chromosome Anatomy 0.000 claims description 9
- 241000287828 Gallus gallus Species 0.000 claims description 7
- -1 phospho Chemical class 0.000 claims description 7
- 108010085238 Actins Proteins 0.000 claims description 4
- 102000007469 Actins Human genes 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 164
- 108020004414 DNA Proteins 0.000 description 146
- 241001493065 dsRNA viruses Species 0.000 description 84
- 239000007758 minimum essential medium Substances 0.000 description 83
- 239000000243 solution Substances 0.000 description 73
- 108090000994 Catalytic RNA Proteins 0.000 description 49
- 102000053642 Catalytic RNA Human genes 0.000 description 49
- 108091092562 ribozyme Proteins 0.000 description 49
- 239000005090 green fluorescent protein Substances 0.000 description 46
- 238000001890 transfection Methods 0.000 description 43
- 239000012124 Opti-MEM Substances 0.000 description 37
- 108010067390 Viral Proteins Proteins 0.000 description 36
- 239000000203 mixture Substances 0.000 description 33
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 31
- 239000012091 fetal bovine serum Substances 0.000 description 31
- 239000000047 product Substances 0.000 description 30
- 101710091045 Envelope protein Proteins 0.000 description 29
- 101710188315 Protein X Proteins 0.000 description 29
- 230000000694 effects Effects 0.000 description 26
- 238000010276 construction Methods 0.000 description 24
- 239000012634 fragment Substances 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- 102100034349 Integrase Human genes 0.000 description 23
- 238000011084 recovery Methods 0.000 description 22
- 238000000246 agarose gel electrophoresis Methods 0.000 description 20
- 238000000746 purification Methods 0.000 description 19
- 241000700618 Vaccinia virus Species 0.000 description 18
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 16
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 16
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 15
- 101710137500 T7 RNA polymerase Proteins 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 15
- 229910052698 phosphorus Inorganic materials 0.000 description 15
- 101150034814 F gene Proteins 0.000 description 14
- 238000012258 culturing Methods 0.000 description 14
- 230000001939 inductive effect Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 241000712079 Measles morbillivirus Species 0.000 description 13
- 102000004142 Trypsin Human genes 0.000 description 13
- 108090000631 Trypsin Proteins 0.000 description 13
- 239000012588 trypsin Substances 0.000 description 13
- 241000712003 Human respirovirus 3 Species 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 241000726041 Human respirovirus 1 Species 0.000 description 11
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 11
- 241000711897 Rinderpest morbillivirus Species 0.000 description 11
- 239000006143 cell culture medium Substances 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 241000711404 Avian avulavirus 1 Species 0.000 description 10
- 241000712083 Canine morbillivirus Species 0.000 description 10
- 239000013613 expression plasmid Substances 0.000 description 10
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 9
- ZHNHJYYFCGUZNQ-KBIXCLLPSA-N Glu-Ile-Ser Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O ZHNHJYYFCGUZNQ-KBIXCLLPSA-N 0.000 description 9
- 241001559185 Mammalian rubulavirus 5 Species 0.000 description 9
- 241000711899 Phocine morbillivirus Species 0.000 description 9
- 108700005077 Viral Genes Proteins 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 241001428894 Small ruminant morbillivirus Species 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 7
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 7
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000012096 transfection reagent Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 6
- 101150008820 HN gene Proteins 0.000 description 6
- 208000005647 Mumps Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 208000010805 mumps infectious disease Diseases 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010046276 FLP recombinase Proteins 0.000 description 5
- 102000004961 Furin Human genes 0.000 description 5
- 108090001126 Furin Proteins 0.000 description 5
- 241000712041 Human parainfluenza virus 4a Species 0.000 description 5
- 241000712036 Human parainfluenza virus 4b Species 0.000 description 5
- 241001559187 Human rubulavirus 2 Species 0.000 description 5
- 101710181008 P protein Proteins 0.000 description 5
- 101710177166 Phosphoprotein Proteins 0.000 description 5
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 description 5
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000012224 gene deletion Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 108010051219 Cre recombinase Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 4
- 241001113283 Respirovirus Species 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 241000702191 Escherichia virus P1 Species 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 101710085938 Matrix protein Proteins 0.000 description 3
- 101710127721 Membrane protein Proteins 0.000 description 3
- 101150118742 NP gene Proteins 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 101150084044 P gene Proteins 0.000 description 3
- 241000711504 Paramyxoviridae Species 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 101710198474 Spike protein Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 241000288669 Tupaia Species 0.000 description 3
- 108010084455 Zeocin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000004779 membrane envelope Anatomy 0.000 description 3
- 230000005486 microgravity Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 241000711895 Bovine orthopneumovirus Species 0.000 description 2
- 241000712005 Bovine respirovirus 3 Species 0.000 description 2
- 241001481833 Coryphaena hippurus Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 241000893570 Hendra henipavirus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000712045 Morbillivirus Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 241000526636 Nipah henipavirus Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 230000007022 RNA scission Effects 0.000 description 2
- 241000711931 Rhabdoviridae Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000723677 Tobacco ringspot virus Species 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241001455610 Ephemerovirus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 101000802734 Homo sapiens eIF5-mimic protein 2 Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101150062031 L gene Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004107 Penicillin G sodium Substances 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 108020005543 Satellite RNA Proteins 0.000 description 1
- 101900194079 Sendai virus Matrix protein Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 108700010774 hepadnaviridae proteins Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019369 penicillin G sodium Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000003168 reconstitution method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000003730 rna directed rna polymerase inhibitor Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108010027510 vaccinia virus capping enzyme Proteins 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005517263A JP4999330B2 (ja) | 2004-01-22 | 2005-01-20 | サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004014653 | 2004-01-22 | ||
| JP2004014653 | 2004-01-22 | ||
| JP2005517263A JP4999330B2 (ja) | 2004-01-22 | 2005-01-20 | サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法 |
| PCT/JP2005/000705 WO2005071092A1 (ja) | 2004-01-22 | 2005-01-20 | サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012028159A Division JP5438149B2 (ja) | 2004-01-22 | 2012-02-13 | サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2005071092A1 JPWO2005071092A1 (ja) | 2007-09-06 |
| JP4999330B2 true JP4999330B2 (ja) | 2012-08-15 |
Family
ID=34805423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005517263A Expired - Lifetime JP4999330B2 (ja) | 2004-01-22 | 2005-01-20 | サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法 |
| JP2012028159A Expired - Lifetime JP5438149B2 (ja) | 2004-01-22 | 2012-02-13 | サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012028159A Expired - Lifetime JP5438149B2 (ja) | 2004-01-22 | 2012-02-13 | サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8741650B2 (https=) |
| EP (2) | EP2434020B1 (https=) |
| JP (2) | JP4999330B2 (https=) |
| KR (1) | KR101279677B1 (https=) |
| CN (1) | CN1934260B (https=) |
| AU (1) | AU2005206410A1 (https=) |
| CA (1) | CA2553976C (https=) |
| WO (1) | WO2005071092A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0863202T3 (da) * | 1995-11-01 | 2010-09-27 | Dnavec Research Inc | Rekombinant Sendai-virus |
| US20030166252A1 (en) * | 1999-05-18 | 2003-09-04 | Kaio Kitazato | Paramyxovirus-derived RNP |
| AU2003234775A1 (en) * | 2002-04-30 | 2003-11-17 | Dnavec Research Inc. | Vector with modified protease-dependent tropism |
| WO2005042737A1 (ja) * | 2003-11-04 | 2005-05-12 | Dnavec Research Inc. | 遺伝子導入された樹状細胞の製造方法 |
| WO2006001120A1 (ja) * | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | マイナス鎖rnaウイルスを含む抗癌剤 |
| WO2006134917A1 (ja) | 2005-06-14 | 2006-12-21 | Dnavec Corporation | 抗体の作製方法 |
| CA2636600A1 (en) * | 2006-01-17 | 2007-07-26 | Dnavec Corporation | Novel protein expression system |
| CA2654033A1 (en) | 2006-05-31 | 2007-12-06 | Dnavec Corporation | Therapeutic agent for alzheimer's disease |
| KR20090052857A (ko) | 2006-07-13 | 2009-05-26 | 디나벡크 가부시키가이샤 | 비복제형 파라믹소바이러스과 바이러스 벡터 |
| KR100725023B1 (ko) * | 2006-10-16 | 2007-06-07 | 제일모직주식회사 | 카도계 수지를 함유한 수지 조성물 및 그에 의한 패턴의 제조방법, 이를 이용한 컬러필터 |
| JPWO2008096811A1 (ja) | 2007-02-07 | 2010-05-27 | ディナベック株式会社 | 弱毒化マイナス鎖ｒｎａウイルス |
| US20100203027A1 (en) | 2007-04-27 | 2010-08-12 | Kyushu Univeristy National University | Viral vector for gene therapy |
| US9127256B2 (en) | 2008-07-16 | 2015-09-08 | Dnavec Corporation | Method for production of reprogrammed cell using chromosomally unintegrated virus vector |
| US8663981B2 (en) | 2008-08-07 | 2014-03-04 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Optimized promoter sequence |
| JPWO2010050586A1 (ja) | 2008-10-31 | 2012-03-29 | ディナベック株式会社 | 組み換え蛋白質の発現を増強する方法 |
| CA2809515A1 (en) | 2010-08-30 | 2012-03-08 | Dnavec Corporation | Composition for inducing pluripotent stem cell, and use thereof |
| CN102436142B (zh) | 2010-09-29 | 2013-11-06 | 第一毛织株式会社 | 黑色光敏树脂组合物以及使用其的光阻层 |
| KR101367253B1 (ko) | 2010-10-13 | 2014-03-13 | 제일모직 주식회사 | 감광성 수지 조성물 및 이를 이용한 차광층 |
| KR101038126B1 (ko) | 2010-11-30 | 2011-05-31 | 주식회사 엘지생명과학 | 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터 |
| CN102028943A (zh) * | 2010-12-08 | 2011-04-27 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种呼吸道合胞病毒样颗粒疫苗及其制备方法 |
| KR101486560B1 (ko) | 2010-12-10 | 2015-01-27 | 제일모직 주식회사 | 감광성 수지 조성물 및 이를 이용한 차광층 |
| KR101453769B1 (ko) | 2010-12-24 | 2014-10-22 | 제일모직 주식회사 | 감광성 수지 조성물 및 이를 이용한 컬러 필터 |
| US20130325376A1 (en) | 2011-04-07 | 2013-12-05 | Thomas Edwin Turicchi, Jr. | Systems and methods for determining a power phase and/or a phase rotation |
| KR101344786B1 (ko) | 2011-12-02 | 2013-12-26 | 제일모직주식회사 | 컬러필터용 감광성 수지 조성물 및 이를 이용한 컬러필터 |
| FR2986536A1 (fr) * | 2012-02-08 | 2013-08-09 | Lfb Biotechnologies | Unites de transcription et leur utilisation dans des vecteurs d'expression (cho) |
| DK2711426T3 (en) * | 2012-09-24 | 2015-07-13 | Lonza Biologics Plc | Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences |
| KR20140076320A (ko) | 2012-12-12 | 2014-06-20 | 제일모직주식회사 | 감광성 수지 조성물 및 이를 이용한 블랙 스페이서 |
| US9828609B2 (en) | 2013-03-12 | 2017-11-28 | International Park Of Creativity | Biological devices and methods for increasing the production of lycopene from plants |
| US10975358B2 (en) | 2013-09-24 | 2021-04-13 | Id Pharma Co., Ltd. | Method for improving efficiency of inducing pluripotent stem cell |
| FI3628334T3 (fi) | 2014-03-21 | 2023-09-15 | Genzyme Corp | Geenihoito verkkokalvon pigmenttirappeuma |
| CN104404005A (zh) * | 2014-12-22 | 2015-03-11 | 天津瑞普生物技术股份有限公司 | 禽流感病毒ha基因重组腺病毒的制备方法 |
| JP7150241B2 (ja) | 2016-11-17 | 2022-10-11 | 国立感染症研究所長 | 非感染性パラミクソウイルス粒子を用いた感染症ワクチン |
| AU2018261769B2 (en) | 2017-05-05 | 2024-03-14 | The Regents Of The University Of California | Compositions and methods for expressing Otoferlin |
| JP6947825B2 (ja) | 2017-07-21 | 2021-10-13 | 株式会社 アイロムグループ | 標的配列を改変するためのポリヌクレオチドおよびその使用 |
| AU2018306455A1 (en) | 2017-07-26 | 2020-02-27 | Virogin Biotech Canada Ltd | Oncolytic viral vectors and uses thereof |
| EP3744847A4 (en) | 2018-01-22 | 2021-12-08 | Japan as Represented by The Director-General of National Institute of Infectious Diseases | SELECTIVE CD8 POSITIVE T CELL INDUCING VACCINE ANTIGEN |
| US12188041B2 (en) | 2018-11-01 | 2025-01-07 | University Of Florida Research Foundation, Incorporated | Codon optimized otoferlin AAV dual vector gene therapy |
| EP3921032A4 (en) | 2019-02-08 | 2022-11-30 | Decibel Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS |
| CN109929847B (zh) * | 2019-02-27 | 2023-08-15 | 苏州系统医学研究所 | 一种pex26基因、蛋白及其应用 |
| CN114040979B (zh) * | 2019-06-21 | 2024-06-28 | 国立大学法人大阪大学 | 稳定地保持外源基因的人工重组rna病毒的制作方法 |
| CA3157063A1 (en) * | 2019-10-10 | 2021-04-15 | Oncorus, Inc. | Dual viruses and dual oncolytic viruses and methods of treatment |
| CA3159549A1 (en) | 2019-10-30 | 2021-05-06 | Decibel Therapeutics, Inc. | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems |
| AU2021247172A1 (en) | 2020-04-01 | 2022-09-15 | University Of Florida Research Foundation, Incorporated | Dual AAV-MY07A vectors with improved safety for the treatment of USH1B |
| EP4209593A4 (en) | 2020-09-04 | 2024-10-09 | Heartseed Inc. | IPS CELL QUALITY IMPROVING AGENT, METHOD FOR PRODUCING IPS CELLS, IPS CELLS, AND COMPOSITION FOR PRODUCING IPS CELLS |
| JPWO2022138964A1 (https=) | 2020-12-25 | 2022-06-30 | ||
| EP4365298A4 (en) | 2021-06-30 | 2025-09-10 | Repli Tech Co Ltd | METHOD FOR PRODUCING NEGATIVE-STRANDED RNA VIRUS VECTOR AND PRODUCED NEGATIVE-STRANDED RNA VIRUS VECTOR |
| CN115772520B (zh) * | 2021-09-08 | 2023-11-21 | 北京锦篮基因科技有限公司 | 用于治疗庞贝氏病的基因治疗构建体、药物组合物和方法 |
| WO2023127871A1 (ja) | 2021-12-27 | 2023-07-06 | 株式会社レプリテック | 温度感受性のマイナス鎖ｒｎａウイルスまたはウイルスベクターおよびそのｒｎａゲノム |
| JPWO2024195811A1 (https=) | 2023-03-22 | 2024-09-26 | ||
| CN117051040B (zh) * | 2023-08-15 | 2024-10-01 | 北京百普赛斯生物科技股份有限公司 | Vsv△g复制缺陷型病毒制备及应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU629554B2 (en) * | 1988-06-24 | 1992-10-08 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Exogenous gene expression vector containing chick beta-actin gene promoter |
| JP2824434B2 (ja) | 1989-11-28 | 1998-11-11 | 財団法人化学及血清療法研究所 | 新規発現ベクター |
| JP2001283451A (ja) | 1992-05-13 | 2001-10-12 | Matsushita Electric Ind Co Ltd | 記録方法および再生方法 |
| JPH06230752A (ja) | 1992-09-14 | 1994-08-19 | Hitachi Ltd | 表示装置の駆動方法 |
| JPH06230753A (ja) | 1993-01-29 | 1994-08-19 | Fuji Xerox Co Ltd | 画像処理装置 |
| JPH06233879A (ja) | 1993-02-08 | 1994-08-23 | Brother Ind Ltd | ロックミシンのかがり方式変換装置 |
| US5798100A (en) | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
| DK0864645T3 (da) * | 1995-10-31 | 2005-10-24 | Dnavec Research Inc | Negativstrenget RNA-virusvektor med autonom replikeringsaktivitet |
| DK0863202T3 (da) * | 1995-11-01 | 2010-09-27 | Dnavec Research Inc | Rekombinant Sendai-virus |
| EP0884383A4 (en) | 1996-02-29 | 2001-12-05 | Takara Shuzo Co | METHOD FOR CLEANING AND REMOVING VIRUSES. |
| US6596529B1 (en) * | 1997-05-02 | 2003-07-22 | Uab Research Foundation | Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof |
| US6187994B1 (en) | 1997-11-18 | 2001-02-13 | Pioneer Hi-Bred International, Inc. | Compositions and methods for genetic modification of plants |
| DE69925841T2 (de) | 1998-08-11 | 2006-05-11 | Dnavec Research Inc., Tsukuba | Rns virus vektor mit der fähigkeit zur kontaktinfiltration |
| US20030166252A1 (en) * | 1999-05-18 | 2003-09-04 | Kaio Kitazato | Paramyxovirus-derived RNP |
| US20020169306A1 (en) * | 1999-05-18 | 2002-11-14 | Kaio Kitazato | Envelope gene-deficient paramyxovirus vector |
| US20030022376A1 (en) * | 1999-05-18 | 2003-01-30 | Kaio Kitazato | Paramyxovirus-derived RNP |
| KR100739938B1 (ko) | 1999-05-18 | 2007-07-16 | 가부시키가이샤 디나벡크 겐큐쇼 | 엔벨로프 유전자 결손 파라믹소과 바이러스 벡터 |
| US7226786B2 (en) * | 1999-05-18 | 2007-06-05 | Dnavec Research Inc. | Envelope gene-deficient Paramyxovirus vector |
| ATE399206T1 (de) | 1999-05-18 | 2008-07-15 | Dnavec Research Inc | Ribonukleoproteinkomplex aus paramyxovirus |
| EP1067179A1 (en) | 1999-07-09 | 2001-01-10 | Pierre Fabre Medicament | Method to select attenuated paramyxoviridae useful for vaccines and therapeutics |
| EP1211318B1 (en) | 1999-09-06 | 2007-08-08 | DNAVEC Research, Inc. | Paramyxoviruses comprising a modified transcription start sequence |
| JP4791651B2 (ja) | 2000-05-18 | 2011-10-12 | 株式会社ディナベック研究所 | 外来遺伝子導入用パラミクソウイルスベクター |
| JPWO2003025570A1 (ja) | 2001-09-18 | 2004-12-24 | 株式会社ディナベック研究所 | 粒子形成能が低下した（−）鎖ｒｎａウィルスベクターの検査方法および製造方法 |
| AU2003234775A1 (en) * | 2002-04-30 | 2003-11-17 | Dnavec Research Inc. | Vector with modified protease-dependent tropism |
| WO2006001120A1 (ja) * | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | マイナス鎖rnaウイルスを含む抗癌剤 |
| AU2006237903A1 (en) * | 2005-04-20 | 2006-10-26 | Dna Vec Corporation | Highly safe intranasally administrable gene vaccines for treating Alzheimer's disease |
| CA2654033A1 (en) * | 2006-05-31 | 2007-12-06 | Dnavec Corporation | Therapeutic agent for alzheimer's disease |
-
2005
- 2005-01-20 JP JP2005517263A patent/JP4999330B2/ja not_active Expired - Lifetime
- 2005-01-20 AU AU2005206410A patent/AU2005206410A1/en not_active Abandoned
- 2005-01-20 EP EP11162419.3A patent/EP2434020B1/en not_active Expired - Lifetime
- 2005-01-20 US US10/586,142 patent/US8741650B2/en active Active
- 2005-01-20 EP EP05703933A patent/EP1717317A4/en not_active Withdrawn
- 2005-01-20 KR KR1020067016708A patent/KR101279677B1/ko not_active Expired - Fee Related
- 2005-01-20 CN CN2005800091828A patent/CN1934260B/zh not_active Expired - Lifetime
- 2005-01-20 WO PCT/JP2005/000705 patent/WO2005071092A1/ja not_active Ceased
- 2005-01-20 CA CA2553976A patent/CA2553976C/en not_active Expired - Lifetime
-
2012
- 2012-02-13 JP JP2012028159A patent/JP5438149B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1717317A4 (en) | 2009-02-11 |
| KR20070004636A (ko) | 2007-01-09 |
| EP2434020A2 (en) | 2012-03-28 |
| CA2553976A1 (en) | 2005-08-04 |
| JP2012130346A (ja) | 2012-07-12 |
| AU2005206410A1 (en) | 2005-08-04 |
| US20070161110A1 (en) | 2007-07-12 |
| CA2553976C (en) | 2013-09-24 |
| CN1934260B (zh) | 2013-03-13 |
| EP2434020B1 (en) | 2014-11-05 |
| CN1934260A (zh) | 2007-03-21 |
| WO2005071092A1 (ja) | 2005-08-04 |
| JP5438149B2 (ja) | 2014-03-12 |
| EP1717317A1 (en) | 2006-11-02 |
| JPWO2005071092A1 (ja) | 2007-09-06 |
| US8741650B2 (en) | 2014-06-03 |
| KR101279677B1 (ko) | 2013-06-27 |
| EP2434020A3 (en) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4999330B2 (ja) | サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法 | |
| JP3602058B2 (ja) | エンベロープ遺伝子欠損パラミクソ科ウイルスベクター | |
| JP3766596B2 (ja) | パラミクソウイルスに由来するｒｎｐ | |
| US6746860B1 (en) | Paramyxovirus vectors used for transfer of foreign genes | |
| JPWO2000070070A1 (ja) | エンベロープ遺伝子欠損パラミクソ科ウイルスベクター | |
| KR20050062634A (ko) | Ｔ 세포에 유전자를 도입하는 방법 | |
| KR20090052857A (ko) | 비복제형 파라믹소바이러스과 바이러스 벡터 | |
| JPWO2005071085A1 (ja) | ウイルスベクターの製造方法 | |
| JPWO2008096811A1 (ja) | 弱毒化マイナス鎖ｒｎａウイルス | |
| JP4791651B2 (ja) | 外来遺伝子導入用パラミクソウイルスベクター | |
| EP1642966B1 (en) | Minus strand rna viral vectors carrying a gene with altered hypermutable regions | |
| US20060216824A1 (en) | Paramyxovirus vector encoding ribozyme and utilization thereof | |
| WO2006137517A1 (ja) | 幼少個体への遺伝子導入用ベクター | |
| HK1094898A (en) | Methods for producing minus-strand rna viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken beta-actin promoter | |
| HK1083110A (en) | Paramyxovirus vector encoding ribozyme and utilization thereof | |
| HK1133675A (en) | Non-replicating paramyxoviridae virus vector | |
| HK1088038A (en) | Minus strand rna viral vectors carrying a gene with altered hypermutable regions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080108 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110225 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120213 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120220 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120418 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120515 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4999330 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150525 Year of fee payment: 3 |
|
| S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |